Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.50 |
| ▸ | IL1RN | P18510 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22619001 | 0.81 | PFKFB3 (0.41) | KMT2AMEN1ALDH1A1CA2CA12 | |
| SCHEMBL22928041 | 0.78 | EGFR (0.42) | ALDH1A1CA2PFKFB3PGRPOLB | |
| SCHEMBL6403890 | 0.72 | HTR6 (0.50) | PKMALDH1A1CA2CA12CA9 | |
| SCHEMBL8557579 | 0.70 | — | — | |
| SCHEMBL8164647 | 0.70 | GLO1 (0.55) | KEAP1IL1RNERAP1KMT2AMEN1 | |
| SCHEMBL22928232 | 0.69 | SMN1; SMN2 (0.40) | KMT2AMEN1ALDH1A1GAAMAPT | |
| Biphenyl SCHEMBL5706278 | 0.69 | CA2 (0.47) | CA2CA12CA9CA1 | |
| SCHEMBL11004258 | 0.68 | MEN1 (0.35) | KMT2AMEN1ALDH1A1PFKFB3POLB | |
| SCHEMBL3477694 | 0.68 | BRD4 (0.52) | KEAP1IL1RNERAP1KMT2AMEN1 | |
| SCHEMBL7416555 | 0.68 | PKM (0.46) | PKMALDH1A1CA12CA9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435364-B2 | Compounds for use as bromodomain inhibitors | ALBERT LUDWIGS UNIVERSITÄT FREIBURG (DE) | 2019-10-08 | — | — | US | disclosed |
| EP-2996689-A1 | COMPOUNDS FOR USE AS BROMODOMAIN INHIBITORS | Albert-Ludwigs-Universität Freiburg (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-20160068485-A1 | COMPOUNDS FOR USE AS BROMODOMAIN INHIBITORS | ALBERT LUDWIGS UNIVERSITÄT FREIBURG (DE) | 2016-03-10 | — | — | US | disclosed |
| WO-2014170350-A1 | COMPOUNDS FOR USE AS BROMODOMAIN INHIBITORS | ALBERT LUDWIGS UNIVERSITÄT FREIBURG (DE) | 2014-10-23 | — | — | WO | disclosed |
| EP-2792355-A1 | Compounds for use as bromodomain inhibitors | Albert-Ludwigs-Universität Freiburg (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-20100022568-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR EARLY STAGE IDIOPATHIC PULMONARY FIBROSIS | Actelion Pharmaceeuticals Ltd. (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068485-A1 | COMPOUNDS FOR USE AS BROMODOMAIN INHIBITORS | BRD1, BRDT, BRD4 | KEAP1 1254/4885IL1RN 178/4885ERAP1 894/4885 |
| US-10435364-B2 | Compounds for use as bromodomain inhibitors | BRD1, BRDT, BRD4 | KEAP1 1254/4885IL1RN 178/4885ERAP1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.